稳定型Weber B型踝关节骨折三周与六周固定比较:随机多中心非劣效临床试验
该随机、实用、非劣效临床试验纳入247例骨骼成熟、孤立性Weber B型腓骨骨折且踝穴一致的患者,比较三周石膏或简单矫形器固定与常规六周石膏固定。12个月时Olerud-Molander踝关节评分(OMAS)显示,三周固定组与六周固定组差异的95%置信区间均未包含预设非劣效界值-8.8分,表明三周固定非劣效于六周固定。
要点
- 稳定型Weber B型踝关节骨折三周石膏或矫形器固定非劣效于六周石膏固定。
- 12个月OMAS组间差异的95%置信区间未跨越预设非劣效界值-8.8分。
- 三周矫形器组 compared with 六周石膏组,踝跖屈略改善且深静脉血栓发生率有统计学差异。
核心结论
- 对于孤立性稳定型Weber B型踝关节骨折,三周石膏或矫形器固定非劣效于常规六周石膏固定。
研究设计与样本
- 随机、实用、非劣效临床试验,结局评估盲法,在芬兰两家主要创伤中心开展,2012年12月22日至2016年6月6日。
- 纳入247例骨骼成熟、年龄16岁及以上、孤立性Weber B型腓骨骨折且静态踝关节X线示踝穴一致的患者。
- 随机分配至常规六周石膏固定组(n=84)、三周石膏固定组(n=83)或三周简单矫形器组(n=80)。
主要发现
- 52周时平均OMAS:六周石膏组87.6(SD 18.3),三周石膏组91.7(SD 12.9),三周矫形器组89.8(SD 18.4)。
- 52周时三周石膏组 versus 六周石膏组的组间差异为3.6分(95%CI -1.9至9.1,P=0.20)。
- 52周时三周矫形器组 versus 六周石膏组的组间差异为1.7分(95%CI -4.0至7.3,P=0.56)。
- 两项主要比较的置信区间均未包含预设非劣效界值-8.8分。
- 次要结局和伤害中仅见三周矫形器组 versus 六周石膏组在踝跖屈轻微改善和深静脉血栓发生率上差异有统计学意义。
关键数值与推荐
- 主要非劣效意向性治疗结局为12个月时Olerud-Molander踝关节评分(OMAS,范围0-100,分数越高结局越好、症状越少)。
- 主要结局预设非劣效界值为-8.8分。
- 247例随机参与者中212例(86%)完成研究。
临床怎么用
- 对孤立性稳定型Weber B型踝关节骨折,可考虑三周石膏或简单矫形器固定替代常规六周石膏固定。
局限性
- 247例随机参与者中仅212例(86%)完成研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether treatment of isolated stable Weber B type ankle fractures with a cast or a simple orthotic device for three weeks produces non-inferior outcomes compared with conventional immobilisation in a cast for six weeks. DESIGN: Randomised, pragmatic, non-inferiority, clinical trial with blinded outcome assessment. SETTING: Two major trauma centres in Finland, 22 December 2012 to 6 June 2016. PARTICIPANTS: 247 skeletally mature patients aged 16 years or older with an isolated Weber B type fibula fracture and congruent ankle mortise in static ankle radiographs. INTERVENTIONS: Participants were randomly allocated to conventional six week cast immobilisation (n=84) or three week treatment either in a cast (n=83) or in a simple orthosis (n=80). MAIN OUTCOME MEASURES: The primary, non-inferiority, intention-to-treat outcome was the Olerud-Molander Ankle Score at 12 months (OMAS; range 0-100; higher scores indicate better outcomes and fewer symptoms). The predefined non-inferiority margin for the primary outcome was -8.8 points. Secondary outcomes were ankle function, pain, quality of life, ankle motion, and radiographic outcome. Follow-up assessments were performed at 6, 12, and 52 weeks. RESULTS: 212 of 247 randomised participants (86%) completed the study. At 52 weeks, the mean OMAS was 87.6 (SD 18.3) in the six week cast group, 91.7 (SD 12.9) in the three week cast group, and 89.8 (SD 18.4) in the three week orthosis group. The between group difference at 52 weeks for the three week cast versus six week cast was 3.6 points (95% confidence interval -1.9 to 9.1, P=0.20), and for the three week orthosis versus six week cast was 1.7 points (-4.0 to 7.3, P=0.56). In both comparisons, the confidence intervals did not include the predefined inferiority margin of -8.8 points. The only statistically significant between group differences observed in the secondary outcomes and harms in the two primary comparisons were slight improvement in ankle plantar flexion and incidence of deep vein thrombosis, both in the three week orthosis group versus six week cast group. CONCLUSION: Immobilisation for three weeks with a cast or orthosis was non-inferior to conventional cast immobilisation for six weeks in the treatment of an isolated stable Weber B type fracture. TRIAL REGISTRATION: ClinicalTrials.gov NCT01758835.
引用
- Kortekangas T, Haapasalo H, Flinkkilä T, et al. Three week versus six week immobilisation for stable Weber B type ankle fractures: randomised, multicentre, non-inferiority clinical trial. BMJ. 2019. PMID: 30674451. doi:10.1136/bmj.k5432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。